Updated
- Log In
- Newsletters
-
Subscribe
Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Biotechnology
Biogen's Slump Is Likely to Continue
Avoid the long side of Biogen as the October low is likely to be tested or broken in the days ahead.
Here's a Handful of Small Biotechs Where Insiders Are Buying
Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.
Here Are 3 Small-Cap Names for Biotech Investors to Consider
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Gilead Sciences Names Roche's O'Day as CEO and Chairman
Daniel O'Day will take over the helm of the biopharmaceutical giant on March 1, 2019.
3 Profitable Small Biotech Names to Consider
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Biotech Moderna Slides in Its Trading Debut
Drug developing startup Moderna Inc. raises $604.3 million for an initial public offering running up to its expected Nasdaq debut Friday.
A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues
It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.
What Is the Fourth Industrial Revolution?
Are we in the middle of a Fourth Industrial Revolution? What impact could new technological advances have on the world?
Bristol-Myers Drops After Lung-Cancer Drug Study Fails
Shares decline after the company says a lung-cancer study it had been working on failed.
Here's a Handful of Ways to Navigate Biotech's Choppy Seas
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.